Status:
UNKNOWN
Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms
Lead Sponsor:
Gundersen Lutheran Medical Foundation
Conditions:
Ureteral Diseases
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.
Detailed Description
Ureteral stents are commonly used to maintain patency of the ureter and are placed for several common reasons including ureteral obstruction due to nephrolithiasis, cancer, or fibrosis as well as afte...
Eligibility Criteria
Inclusion
- Patients between the ages of 18 and 70 years old.
- Planning to undergo ureteroscopy with ureteral stent placement at our site.
- Able to read and understand an English language survey (USSQ).
Exclusion
- Patients who are unable to provide informed consent.
- Patients who are already taking an alpha-blocker.
- Patients with hypersensitivity or known adverse side effects of tamsulosin or its ingredients and those who are not candidates for tamsulosin per attending Urologist discretion.
- Patients with a preexisting bladder condition including UTI within 30 days of the procedure.
- Patients with hepatitis C on boceprevir.
- Patients who have medical conditions known to be associated with chronic pain, those taking medications for chronic pain such as gabapentin or a chronic opioid per the judgement of the PI, or those with a pain contract on file.
- Women who are pregnant or planning to become pregnant.
Key Trial Info
Start Date :
February 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03799120
Start Date
February 18 2019
End Date
December 1 2021
Last Update
February 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gundersen Health System
La Crosse, Wisconsin, United States, 54601